ArticleBrain tumor pathology2026
Case report of a rare TCF3::BEND2-fused primary intracranial neuroepithelial neoplasm in a female child.
Article in Brain tumor pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Astroblastoma, MN1-altered, is a rare circumscribed glial neoplasm defined by alterations in the MN1 gene and often the MN1::BEND2 fusion. However, it is noted that a subset of these tumors lacks the classic astroblastic perivascular pseudorosettes, which can complicate diagnosis. We report a diagnostically challenging case in a 6-year-old female presenting with gait disturbance and limb weakness. MRI identified a well-defined fourth ventricular roof mass causing obstructive hydrocephalus. Histology post-resection revealed a solid tumor composed of epithelioid cells arranged in sheets and nests, exhibiting abundant cytoplasm, nuclear atypia, and prominent grooves, but no astroblastic pseudorosettes or significant mitosis. Immunohistochemically, tumor cells were negative for GFAP and Olig2, showed only focal EMA expression, but exhibited diffuse PR positivity. Methylation profiling did not match any established WHO CNS5 subtype, while targeted NGS identified a defining TCF3::BEND2 in-frame fusion. This case supports the existence of a phenotypically distinct variant within the spectrum of BEND2-rearranged neuroepithelial tumors, characterized by the TCF3::BEND2 fusion. Although molecularly related to MN1-altered astroblastoma, it displays distinct histological and immunophenotypic features. These findings further support the role of BEND2 as a potential oncogenic driver and underscore the importance of recognizing this fusion-defined tumor as a distinct variant within the astroblastoma-like spectrum.
Indexed as
Identifiers
42120806What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.